Kb) | (616

: Despite the high rate of stopping, the overall survival and progression-free survival (estimated at 35 months) remained excellent. Real-World vs. Clinical Trials

: Interestingly, the most common reason for stopping the drug was toxicity (intolerance) rather than the leukemia getting worse (disease progression). (616 KB)

: Investigating approaches where patients only take the drug for a set period, especially if they achieve a complete response, to avoid unnecessary long-term exposure and side effects. If you'd like, I can: : Despite the high rate of stopping, the

The authors argue that because the drug is highly effective but often hard to tolerate, the medical community should focus on: : Investigating approaches where patients only take the

This article, available through PubMed Central (PMC) , provides a comprehensive look at how the drug performs in real-world clinical settings compared to controlled trials. Study Overview: The 616-Patient Cohort

The search for a "616 KB" article points directly to a significant medical study titled